Weekly NADAC Price Changes
A weekly executive brief covering the pricing movements that matter most to market strategy and reimbursement planning.
NADAC Weekly Brief: AbbVie's Immunology Portfolio Drives Net Gains as Ustekinumab and Paliperidone Pull Prices Down
For the week ending August 19, 2026, NADAC pricing showed mixed movement across major therapeutic categories. AbbVie Inc. posted the largest aggregate manufacturer swing at $2.9M across 71 products, largely offsetting a $2.1M decline tied to Interleukin-12 Antagonist drugs (Ustekinumab). Risankizumab-rzaa led market-level gains at $2.7M (+0.3%), while Paliperidone Palmitate and Janssen-manufactured products registered notable declines. The Opioid Antagonist class emerged as the most pressured category, rising 1.2% and contributing $870.4K in impact across 107 drugs. Overall market movement remained tight, with most top-mover NDCs shifting less than 1% week-over-week.
Key takeaways
- AbbVie Inc. recorded the largest manufacturer-level gain ($2.9M across 71 products), while Janssen Biotech and Janssen Pharmaceuticals both saw declines exceeding $1.1M each.
- Interleukin-12 Antagonist (Ustekinumab) drove the week's largest relief at -$2.1M, while Interleukin-23 Antagonist and Risankizumab-rzaa moved in the opposite direction with gains of $860.9K and $2.7M respectively.
- Opioid Antagonist was the most pressured therapeutic class this week, up 1.2% and contributing $870.4K in impact across 107 drugs, warranting continued monitoring for formulary and reimbursement impact.
What to watch
Interleukin-12 vs. Interleukin-23 Divergence
Ustekinumab (Interleukin-12 Antagonist) declined $2.1M while Risankizumab-rzaa and Interleukin-23 Antagonist products gained $2.7M and $860.9K respectively. Payers should watch for continued divergence in this competitive immunology space.
GLP-1 Receptor Agonist Softening
The GLP-1 Receptor Agonist class fell 0.9%, a $959.1K impact across 41 drugs. Procurement teams should track whether this downward trend continues into next week's release.
Opioid Antagonist Cost Pressure
This class posted the highest weighted increase this week (+1.2%, $870.4K impact across 107 drugs). Pharmacy and payer teams should monitor for sustained upward pressure in upcoming releases.
Largest cost pressure
Largest absolute weekly price increase in the current release
Largest relief
Largest absolute weekly price decline in the current release
Top 10 NDCs by weekly price movement
Up to 10 changed products are shown. Each edition preserves its published price comparison.
| Drug | Manufacturer | NDC | Prev. price | Current price | Change |
|---|---|---|---|---|---|
| STELARA 90 MG/ML SYRINGE | Janssen Biotech, Inc. | 57894006103 | $29,843.8000 | $29,792.7867 | -0.2% |
| SKYRIZI 150 MG/ML PEN | AbbVie Inc. | 00074210001 | $22,731.9941 | $22,761.4629 | +0.1% |
| UZEDY ER 125 MG/0.35 ML SYRING | Teva Pharmaceuticals USA Inc. | 51759063010 | $9,274.1673 | $9,327.3766 | +0.6% |
| TREMFYA 100 MG/ML ONE-PRESS | Janssen Biotech, Inc. | 57894064011 | $14,710.0533 | $14,745.8421 | +0.2% |
| INVEGA SUSTENNA 234 MG/1.5 ML | Janssen Pharmaceuticals Inc. | 50458056401 | $2,340.7504 | $2,338.6332 | -0.1% |
| SKYRIZI 150 MG/ML SYRINGE | AbbVie Inc. | 00074105001 | $22,757.3500 | $22,887.4386 | +0.6% |
| SKYRIZI 360 MG/2.4 ML ON-BODY | AbbVie Inc. | 00074107001 | $9,537.2715 | $9,565.6005 | +0.3% |
| NALOXONE HCL 4 MG NASAL SPRAY | Padagis Israel Pharmaceuticals Ltd | 45802057884 | $15.8776 | $16.9224 | +6.6% |
| COSENTYX UNOREADY 300 MG/2 ML PEN (1 PEN) | Novartis Pharmaceuticals Corporation | 00078107068 | $4,082.8563 | $4,088.1014 | +0.1% |
| NORDITROPIN FLEXPRO 10 MG/1.5 | Novo Nordisk | 00169770521 | $1,145.4686 | $1,137.1764 | -0.7% |
Drug market summaries
Manufacturer movement
Notes and methodology
How the weekly brief calculations were ranked, aggregated, and preserved for archive consistency.
Top mover ranking
The Top 10 table ranks NDCs by absolute weekly impact: the change in unit price multiplied by dispensing exposure when available.
Segment summaries
Drug markets, manufacturers, and therapeutic classes aggregate the same NDC-level deltas. Average move is the mean percent change, while impact is the summed dollar-weighted effect using dispensing-volume exposure when that dataset is available.
Headline cards and archive stability
Most pressured class selects the largest positive class impact, and largest manufacturer swing selects the manufacturer with the largest aggregate absolute impact. Every weekly brief stores a frozen snapshot so archived pages do not drift when live NADAC data changes.
More archived editions
Each edition is permanently archived under its release date.
Week of September 30, 2026
NADAC weekly update: 14 NDCs changed — 2026-09-30
The CMS publication dated 2026-09-30 contains 30,079 priced NDCs in our data. Of the 29,945 NDCs also priced in the 2026-09-23 publication, 14 changed and 29,931 were unchanged. This edition reports the available updates; a small number of changes does not establish a market-wide trend.
Week of September 23, 2026
NADAC Week of Sep 23: Biosimilar Surge Drives Cost Pressure While Broader Market Skews Lower
The September 23, 2026 NADAC release compared against September 16 shows a market with more line-item decreases (15,294) than increases (13,311) across 29,892 comparable NDCs, indicating a mild net downward bias in pricing activity despite a few large upside outliers. The standout event is a $3.0M weighted increase in Fulphila (pegfilgrastim-jmdb) from Biocon Biologics, which single-handedly drove the Leukocyte Growth Factor class to the top of this week's cost-pressure rankings and made Biocon the largest manufacturer swing. On the relief side, Kesimpta (ofatumumab) posted the largest single-product decline at $469.9K, while the Corticosteroid class—spanning 1,122 drugs—registered a modest but broad-based $436.6K decrease, reinforcing that downward movement this week is more widely distributed than the upside, which is concentrated in a handful of specialty biologics.
Week of September 16, 2026
NADAC weekly update: no price changes among comparable NDCs — 2026-09-16
The CMS publication dated 2026-09-16 contains 29,936 priced NDCs in our data. Of the 29,915 NDCs also priced in the 2026-09-09 publication, 0 changed and 29,915 were unchanged. This edition reports the available updates; a small number of changes does not establish a market-wide trend.
Explore the broader trend ecosystem
Trends overview
Broader market movement and volatility across the full NADAC dataset.
Manufacturers
Compare suppliers and pricing dispersion across product portfolios.
Drug markets
Review generic alternatives by therapeutic market and current pricing.
Therapeutic classes
See category-level swings by prescribing class and market segment.
Understanding NADAC pricing
A primer on how NADAC works and why weekly movement matters.
Methodology
How the data is normalized and aggregated for public reporting.